Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:24 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 532649 | NSE: NECLIFE

Nectar Lifescience Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹43.87Undervalued by 349.49%vs CMP ₹9.76

P/E (15.0) × ROE (11.2%) × BV (₹32.00) × DY (2.00%)

Defaults: P/E=15

₹30.26Undervalued by 210.04%vs CMP ₹9.76
MoS: +67.7% (Strong)Confidence: 64/100 (Moderate)Models: All 4: Undervalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹24.6241%Under (+152.3%)
Net Asset ValueAssets₹36.7824%Under (+276.8%)
ROCE CapitalReturns₹20.5716%Under (+110.8%)
Revenue MultipleRevenue₹42.7418%Under (+337.9%)
Consensus (4 models)₹30.26100%Undervalued
Key Drivers: EPS CAGR -43.9% drags value — could be higher if earnings stabilize.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -43.9% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

45
Nectar Lifescience Ltd scores 45/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health41/100 · Moderate
ROCE 5.4% WeakROE 11.2% AverageD/E 0.79 ModerateInterest Coverage 0.0x RiskyProfitable 2/5 years Inconsistent
Smart Money60/100 · Moderate
FII holding stable No changePromoter increased by 6.93% Positive
Earnings Quality60/100 · Moderate
OPM stable around 4% SteadyWorking capital: 43 days (improving) Efficient
Quarterly Momentum35/100 · Weak
Revenue (4Q): -46% YoY DecliningProfit (4Q): -2,072% YoY DecliningOPM: 0.0% (up 500.0% YoY) Margin expansion
Industry Rank30/100 · Weak
ROCE 5.4% vs industry 16.4% Below peers3Y sales CAGR: 0% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Nectar Lifescience Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
30/100
Low
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 0.0 vs Ind 53.8 | ROCE 5.4% | ROE 11.2% | CFO/NP N/A
Balance Sheet Stress
10/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.79x | IntCov 0.0x | Current 1.04x | Borrow/Reserve 0.66x
Cash Flow Reliability
100/100
Strong
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹-114 Cr | CFO/NP N/A
Ownership Accumulation
+50
Accumulation
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII +0.06 pp | DII 0.00 pp | Prom +6.93 pp
Business Momentum
-100
Early weakness
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales -100.0% | Q NP +108.0% | Q OPM -77.0 pp
Derived FieldValueHow it is derived
Valuation Gap %+210.0%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves0.66xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII Change+0.06 ppLatest FII% minus previous FII%
DII Change0.00 ppLatest DII% minus previous DII%
Promoter Change+6.93 ppLatest promoter% minus previous promoter%
Shareholder Count Change-1,476Latest shareholder count minus previous count
Quarterly Sales Change-100.0%Latest quarter sales vs previous quarter sales
Quarterly Profit Change+108.0%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change-77.0 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:24 am

Market Cap 190 Cr.
Current Price 9.76
Intrinsic Value₹30.26
High / Low 28.3/9.20
Stock P/E
Book Value 32.0
Dividend Yield0.00 %
ROCE5.36 %
ROE11.2 %
Face Value 1.00
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Nectar Lifescience Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Nectar Lifescience Ltd 190 Cr. 9.76 28.3/9.20 32.00.00 %5.36 %11.2 % 1.00
Lyka Labs Ltd 183 Cr. 51.2 129/44.1 28.30.00 %9.91 %9.31 % 10.0
Ambalal Sarabhai Enterprises Ltd 203 Cr. 26.5 42.0/23.111.4 19.20.00 %9.12 %6.25 % 10.0
Gennex Laboratories Ltd 208 Cr. 8.55 17.2/7.0511.9 8.790.00 %13.0 %10.2 % 1.00
Auro Laboratories Ltd 169 Cr. 272 317/15957.4 69.90.00 %3.85 %4.33 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Nectar Lifescience Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 34438939439845244135960431510
Expenses 34337135937141039331960585602
Operating Profit 1183627424840-1-0-154-11-2
OPM % 0%5%9%7%9%11%11%-10%-500%-36%-16%77%
Other Income 1318011011780-62-17635
Interest 1720182125242000180030
Depreciation 151515151515150016100
Profit before tax -18232211558-188-64-1763
Tax % -47%-145%41%38%36%95%40%-2%2%-31%-1%0%-339%
Net Profit -942121368-130-63-17614
EPS in Rs -0.410.160.080.050.070.030.130.250.35-5.80-2.82-7.850.64

Last Updated: February 4, 2026, 8:46 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 4:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1,6341,6381,6741,6351,8742,7792,3631,5411,6651,5201,6821,664437
Expenses 1,3451,3711,4361,4111,6382,5142,1431,4321,5071,4671,5301,694593
Operating Profit 28926723922423626422010915953152-30-157
OPM % 18%16%14%14%13%10%9%7%10%3%9%-2%-36%
Other Income 1220623664-221143155-203
Interest 1381261231171151481261127979877548
Depreciation 84775762646361605759616216
Profit before tax 78856467635937-8534-4218-162-424
Tax % 21%22%15%18%17%19%15%-14%26%-43%73%-30%
Net Profit 62665455524832-7325-245-114-355
EPS in Rs 2.772.952.422.472.332.121.42-3.271.12-1.080.22-5.07-15.83
Dividend Payout % 4%3%4%2%2%2%4%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)6.45%-18.18%1.85%-5.45%-7.69%-33.33%-328.12%134.25%-196.00%120.83%-2380.00%
Change in YoY Net Profit Growth (%)0.00%-24.63%20.03%-7.31%-2.24%-25.64%-294.79%462.37%-330.25%316.83%-2500.83%

Nectar Lifescience Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:0%
5 Years:-7%
3 Years:0%
TTM:-3%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-3025%
Stock Price CAGR
10 Years:-8%
5 Years:-7%
3 Years:-14%
1 Year:-69%
Return on Equity
10 Years:0%
5 Years:-4%
3 Years:-6%
Last Year:-11%

Last Updated: September 5, 2025, 11:35 am

Balance Sheet

Last Updated: December 4, 2025, 1:42 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 22222222222222222222222222
Reserves 9059369329841,0361,0831,1141,0401,0651,0421,047934694
Borrowings 858925962878955903779903860754636582459
Other Liabilities 609628640696710696718423443371486509639
Total Liabilities 2,3942,5102,5562,5812,7242,7052,6332,3882,3912,1892,1912,0471,815
Fixed Assets 94893490688185282578577272366264363328
CWIP 122919910210010011599857866570
Investments 0111110111111
Other Assets 1,3241,4851,5511,5971,7711,7801,7331,5171,5821,4491,4821,3571,786
Total Assets 2,3942,5102,5562,5812,7242,7052,6332,3882,3912,1892,1912,0471,815

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 255144169199652392852195134225169
Cash from Investing Activity + -90-60-77-18-29-26-33-291752-17-42
Cash from Financing Activity + -161-61-89-204-40-201-25211-119-186-205-128
Net Cash Flow 4233-23-412-04-8-02-1
Free Cash Flow 153648717432204249-10110183195126
CFO/OP 95%56%74%92%33%96%134%23%60%252%148%-574%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-569.00-658.00-723.00-654.00-719.00-639.00-559.00-794.00-701.00-701.00-484.00-612.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 849910711211973618998678276
Inventory Days 240253260270226151192185197212215184
Days Payable 13914615416714280104108112100127117
Cash Conversion Cycle 185207213215203145150166182179170143
Working Capital Days 23404145674653673776343
ROCE %12%11%10%10%9%10%8%3%5%-0%6%-5%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Jan 2026
Promoters 55.80%55.80%55.80%55.80%55.80%55.80%44.53%44.53%44.53%44.91%44.91%51.84%
FIIs 16.00%16.02%16.12%16.98%16.60%3.24%0.73%1.65%0.82%0.62%0.52%0.58%
DIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.15%0.19%0.08%0.00%0.00%
Government 0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%5.84%3.56%
Public 28.18%28.17%28.05%27.20%27.57%40.94%54.72%53.64%54.45%54.37%48.73%44.02%
No. of Shareholders 61,58260,28360,76159,94658,23066,74169,48269,24171,97776,47078,12476,648

Shareholding Pattern Chart

No. of Shareholders

Nectar Lifescience Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) -5.070.22-1.081.12-3.27
Diluted EPS (Rs.) -5.070.22-1.081.12-3.27
Cash EPS (Rs.) -2.292.931.563.66-0.58
Book Value[Excl.RevalReserv]/Share (Rs.) 42.6347.6847.4748.5147.36
Book Value[Incl.RevalReserv]/Share (Rs.) 42.6347.6847.4748.5147.36
Revenue From Operations / Share (Rs.) 74.4775.1067.9474.4268.82
PBDIT / Share (Rs.) -1.107.414.297.575.03
PBIT / Share (Rs.) -3.884.701.655.032.34
PBT / Share (Rs.) -7.200.81-1.891.52-3.78
Net Profit / Share (Rs.) -5.070.22-1.081.12-3.27
NP After MI And SOA / Share (Rs.) -5.070.22-1.081.12-3.27
PBDIT Margin (%) -1.479.866.3110.177.31
PBIT Margin (%) -5.206.252.436.763.40
PBT Margin (%) -9.671.08-2.782.04-5.49
Net Profit Margin (%) -6.800.29-1.581.50-4.74
NP After MI And SOA Margin (%) -6.800.29-1.581.50-4.74
Return on Networth / Equity (%) -11.880.46-2.272.30-6.89
Return on Capital Employeed (%) -8.478.652.858.134.09
Return On Assets (%) -5.550.22-1.101.04-2.96
Long Term Debt / Equity (X) 0.060.130.210.260.12
Total Debt / Equity (X) 0.600.590.700.790.79
Asset Turnover Ratio (%) 0.780.760.660.680.60
Current Ratio (X) 1.261.501.591.561.04
Quick Ratio (X) 0.530.590.620.690.54
Inventory Turnover Ratio (X) 2.051.421.391.651.13
Dividend Payout Ratio (NP) (%) 0.000.000.000.00-1.53
Dividend Payout Ratio (CP) (%) 0.000.000.000.00-8.61
Earning Retention Ratio (%) 0.000.000.000.00101.53
Cash Earning Retention Ratio (%) 0.000.000.000.00108.61
Interest Coverage Ratio (X) -0.321.911.212.161.01
Interest Coverage Ratio (Post Tax) (X) -0.521.060.691.320.57
Enterprise Value (Cr.) 1078.151290.981091.931381.461231.83
EV / Net Operating Revenue (X) 0.640.760.710.820.79
EV / EBITDA (X) -43.897.7711.358.1310.92
MarketCap / Net Operating Revenue (X) 0.300.400.230.320.27
Retention Ratios (%) 0.000.000.000.00101.53
Price / BV (X) 0.530.630.330.490.39
Price / Net Operating Revenue (X) 0.300.400.230.320.27
EarningsYield -0.220.01-0.060.04-0.17

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Nectar Lifesciences Ltd. is a Public Limited Listed company incorporated on 27/06/1995 and has its registered office in the State of Punjab, India. Company's Corporate Identification Number(CIN) is L24232PB1995PLC016664 and registration number is 016664. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1669.97 Cr. and Equity Capital is Rs. 22.43 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsVillage Saidpura, Tehsil Derabassi, Mohali Punjab 140507Contact not found
Management
NamePosition Held
Mr. Sanjiv GoyalChairman & Managing Director
Dr. Surulichamy SenethilkumarDirector - R & D
Dr. Indu Pal KaurIndependent Director
Ms. Meena VermaNominee Director
Dr. Rupinder TewariIndependent Director
Dr. Kuldip Kumar BhasinIndependent Director

FAQ

What is the intrinsic value of Nectar Lifescience Ltd and is it undervalued?

As of 05 April 2026, Nectar Lifescience Ltd's intrinsic value is ₹30.26, which is 210.04% higher than the current market price of ₹9.76, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (11.2 %), book value (₹32.0), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Nectar Lifescience Ltd?

Nectar Lifescience Ltd is trading at ₹9.76 as of 05 April 2026, with a FY2026-2027 high of ₹28.3 and low of ₹9.20. The stock is currently near its 52-week low. Market cap stands at ₹190 Cr..

How does Nectar Lifescience Ltd's P/E ratio compare to its industry?

Nectar Lifescience Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Nectar Lifescience Ltd financially healthy?

Key indicators for Nectar Lifescience Ltd: ROCE of 5.36 % is on the lower side compared to the industry average of 16.35%. Dividend yield is 0.00 %.

Is Nectar Lifescience Ltd profitable and how is the profit trend?

Nectar Lifescience Ltd reported a net profit of ₹-114 Cr in Mar 2025 on revenue of ₹1,664 Cr. Compared to ₹25 Cr in Mar 2022, the net profit shows a declining trend.

Does Nectar Lifescience Ltd pay dividends?

Nectar Lifescience Ltd has a dividend yield of 0.00 % at the current price of ₹9.76. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Nectar Lifescience Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports